10x Genomics, Inc. reported $617M of revenue over the trailing twelve months, −4.3% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $617M (to Q2 2026). Net income: −$75M, trailing twelve months to Q2 2026. Free cash flow: $121M, trailing twelve months to Q2 2026. Operating margin: −14%, trailing twelve months to Q2 2026.

TXG10x Genomics, Inc.

Healthcare

$80.64+518% 1Y

$80.64

$11.3452 weeks$97.82

TXG as reported

10x Genomics, Inc. reported $617M of revenue over the trailing twelve months, −4.3% on the year before. 10 reported series are charted on this page, each one as filed.

$617M

Revenue, trailing twelve months · to Q2 2026 · −4.3% against the twelve months before

Net income: −$75M
Net income · −11% year on year · trailing twelve months to Q2 2026
Free cash flow: $121M
Free cash flow · +114% year on year · trailing twelve months to Q2 2026
Operating margin: −14%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for TXG, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$617M	−4.3%	Q2 2026
Net income	−$75M	−11%	Q2 2026
EPS	−$0.59	−17%	Q2 2026
Gross margin	70%	n/a	Q2 2026
Operating margin	−14%	n/a	Q2 2026
Net margin	−12%	n/a	Q2 2026
ROE	−6.8%	n/a	Q2 2026
ROA	−5.3%	n/a	Q2 2026
ROIC	257%	n/a	Q4 2020 · 22 quarters behind
Free cash flow	$121M	+114%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.